GT Metabolic Solutions Announces Series C Growth Investment Led by J.P. Morgan Life Sciences Private Capital

MINNEAPOLIS–(BUSINESS WIRE)–GT Metabolic™ Solutions, Inc. (“the Company” or “GT Metabolic”), a pioneer in the medical device field and the first to receive FDA De Novo grant and 510(k) clearance for use of magnetic technology to create compression anastomoses (connections between two tubular structures in the body, such as intestines), today announced a Series C growth investment from J.P. Morgan Life Sciences Private Capital. Proceeds from the financing will support the Company’s ongoing glo

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.